αααααβααΎα038290 β’ KOSDAQ
add
Macrogen Inc
16,170.00β©
20 ααΈααΆ, 6:42:58 PM ααααβααα +9 · KRW · KOSDAQ · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
αα·αααΈαα»α
15,950.00β©
α
αααααααααααα
15,970.00β© - 16,390.00β©
α
ααααααα½αααααΆαα
α»αααααα
14,720.00β© - 20,900.00β©
ααΎαβαα»αβααΈααααΆα
175.31Β αααΈααΆα KRW
ααα ααα½αααΌαααααα
46.59Β ααΆαα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
3.09%
ααΆααααααΌαα
αααα
KOSDAQ
ααααααΆαααΈααααΆα
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (KRW) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 49.06Β αααΈααΆα | 48.67% |
α
αααΆαααααα·ααααα·ααΆα | 17.27Β αααΈααΆα | 25.14% |
α
αααΌααα»ααα | 2.46Β αααΈααΆα | 177.27% |
ααααΆααα
αααααα»ααα | 5.01 | 151.97% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | β | β |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 3.81Β αααΈααΆα | 72.55% |
α’ααααΆαααααααααΆαααααα·αααααΆα | -2.28% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (KRW) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 34.59Β αααΈααΆα | 40.60% |
ααααααααα»α | 341.60Β αααΈααΆα | 24.59% |
ααΆαααα½ααα»αααααΌαααα»α | 173.25Β αααΈααΆα | 38.80% |
ααΌαβααααα»α | 168.36Β αααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 10.84Β ααΆα | β |
ααααααααααΉαααααα
| 1.13 | β |
ααα
ααααααΎαααααα | 0.84% | β |
ααα
ααααααΎααΎααα»α | 1.04% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (KRW) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | 2.46Β αααΈααΆα | 177.27% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 7.10Β αααΈααΆα | 441.77% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -12.18Β αααΈααΆα | -27.34% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 6.60Β αααΈααΆα | -1.95% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 1.94Β αααΈααΆα | 143.10% |
ααα αΌαααΆα
αααααΆααααααα | 2.49Β αααΈααΆα | 124.72% |
α’αααΈ
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
ααΆααααααΎαα‘αΎα
5 αα·αα»ααΆ 1997
αααααβαααααΆα
αα»ααααα·α
475